Bioxytran (BIXT) Stock Price, News & Analysis

Company Overview

BioXyTran, Inc. is a biotechnology company focused on developing nanotechnology-based therapeutic products. Its research has centered on methods for delivering oxygen and other therapeutic agents through the bloodstream, with the goal of addressing conditions associated with inadequate blood flow and oxygen deprivation.

The company’s lead development program has been identified as BXT-25, an oxygen-delivery product intended for potential use in ischemic conditions, including acute ischemic stroke. BioXyTran has also described a broader platform for creating nanoparticle-based treatments and has pursued additional applications in areas where improved oxygen transport or targeted delivery may provide therapeutic benefits.

BioXyTran is headquartered in the United States and has operated primarily as a development-stage biotechnology company. Its programs remain focused on research, regulatory development and clinical evaluation, and the company’s product candidates are subject to applicable regulatory requirements before they can be commercialized.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.02 to $0.09
• Volume: 13,700 shs
• Average Volume: 187,980 shs
• Market Capitalization: $2.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bioxytran Stock Analysis - MarketRank™

Bioxytran scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bioxytran.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioxytran is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioxytran is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Bioxytran has been sold short.

Short Interest Ratio / Days to Cover

Bioxytran has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bioxytran has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioxytran does not currently pay a dividend.

Dividend Growth

Bioxytran does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Bioxytran has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bioxytran this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioxytran insiders have not sold or bought any company stock.

Percentage Held by Insiders

70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Bioxytran has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BIXT
• CIK: 1445815
• Web: www.bioxytraninc.com
• Phone: (617) 454-1199
• Fax: N/A
• Employees: 2
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -792.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -1.14

Miscellaneous

• Outstanding Shares: 114,695,000
• Free Float: 34,409,000
• Market Cap: $2.60 million
• Optionable: Not Optionable
• Beta: 2.32